Pharmaceutical company Aspen has concluded an agreement with biopharmaceutical company Amgen to exclusively market, distribute, use and sell Amgen’s products in South Africa for an initial term of five years, which will be renewed. The transaction includes future pipeline products and an opportunity for expansion into the rest of sub-Saharan Africa. Amgen will continue to manufacture and supply its products to Aspen for the duration of the contract, Aspen said in an announcement.
